Peptides are starting to move back into the conversation., After years of restriction under the FDAs 503A Category 2 list, were now seeing momentum toward re evaluation and potential reintroduction FDA's Overreach on Compounded Peptides FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Peptides: Legal and Regulatory Risks 503A Compounding Pharmacies Must Understand Industry Update: Interim 503A and 503B Bulks Lists New Revisions FDA May Reverse Ban on 14 PeptidesWhat It Means for Your Beauty Routine Allure